// App-Quantinova.ai

341 : Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)

Researchers

Presenter

  • Rahul Aggarwal

Principal Investigators

  • Dan Costin

  • Jingsong Zhang

  • Paul Monk

  • Mark Linch

  • Lawrence Karsh

  • Diane Healey

  • Stefani Corsi-Travali

  • Sreenivas Adurthi

  • Adedayo Adedoyin

  • Vincent ONeill

Medical Centers

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • White Plains Hospital, Center for Cancer Care, White Plains, NY, USA

  • H. Lee Moffitt Cancer Cneter and Research Institute, Tampa, FL, USA

  • The Ohio State University Comprehensive, Columbus, OH, USA

  • University College London Cancer Institute, London, UK

  • The Urology Center of Colorado, Denver, CO

  • BioXcel Therapeutics, Madison, CT, USA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Fixed Dose

  • Multicenteric

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved